Monitoring AML1-ETO and CBFbeta-MYH11 transcripts in acute myeloid leukemia.
The core-binding factor (CBF) leukemias comprise acute myeloid leukemia (AML) with t(8;21) and inv(16)/t(16;16), characterized by the presence of the AML1-ETO and CBFbeta-MYH11 fusion genes, respectively. These leukemia-associated genes can now be sensitively and reliably quantified by real-time reverse transcription polymerase chain reaction (RT-PCR) techniques and thus can serve as molecular targets for monitoring residual leukemia. Studies to date suggest that quantitative monitoring of minimal residual disease (MRD) in CBF-positive AML is useful in distinguishing patients at high risk of relapse from those in durable remission. Preliminary results of MRD monitoring by real-time RT-PCR in this subset of AML patients are promising and provide the basis for further evaluation by quantitative analysis in large prospective clinical trials.
Yin
John A Liu
JA
University Department of Haematology, Manchester Royal Infirmary, Manchester, M13 9WL, UK. john.yin@cmmc.nhs.uk
Frost
Lindsay
L
D000208:Acute Disease; D050676:Core Binding Factor Alpha 2 Subunit; D006801:Humans; D007951:Leukemia, Myeloid / Q000378:metabolism* / Q000628:therapy; D008991:Monitoring, Physiologic; D018365:Neoplasm, Residual; D015514:Oncogene Proteins, Fusion / Q000235:genetics / Q000378:metabolism*; D016133:Polymerase Chain Reaction; D011379:Prognosis; D012334:RNA, Neoplasm / Q000378:metabolism; D000075142:RUNX1 Translocation Partner 1 Protein; D014157:Transcription Factors / Q000235:genetics / Q000378:metabolism*
C107844:AML1-ETO fusion protein, human; C095514:CBFbeta-MYH11 fusion protein; D050676:Core Binding Factor Alpha 2 Subunit; D015514:Oncogene Proteins, Fusion; D012334:RNA, Neoplasm; D000075142:RUNX1 Translocation Partner 1 Protein; D014157:Transcription Factors